首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Research

Cancer Research杂志,由American Association for Cancer Research Inc.出版,于1941年创刊,Semimonthly,出版语言English,ISSN:0008-5472,E-ISSN:1538-7445。

投稿咨询
Cancer Research
Cancer Research
Cancer Research
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
22.6
CiteScore
17
期刊收录
SCI、SCIE

Cancer Research(中文译名:《癌症研究》),ISSN:0008-5472,EISSN:1538-7445,是American Association for Cancer Research Inc.出版的国际性学术期刊,创刊于1941年,以Semimonthly形式稳定发行,2026年总发文量约291篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达22.6,2025年期刊CiteScore为17,2025年期刊自引率约0.9%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer Research长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约2.5月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Japan、England、GERMANY (FED REP GER)、Canada、France等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMHARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、DANA-FARBER CANCER INSTITUTE、MEMORIAL SLOAN KETTERING CANCER CENTER、UNICANCER、JOHNS HOPKINS UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 16 / 333

95.3

学科:ONCOLOGY SCIE Q1 22 / 333

93.54

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 16 / 328

95.3

学科:ONCOLOGY SCIE Q1 24 / 328

92.84


中国学者近期发文

1
KH617 API manufacturing: A synthetic biology approac

Author:Zhou, Yi; Liu, Jiong-Qin; Gao, Cheng-Guo; Luo, Hao; Zhao, Man-Xi; Ke, Xiao

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB033-LB033. DOI: 10.1158/1538-7445.AM2026-LB033

2
Cytomegalovirus reactivation orchestrates myeloid reprogramming to drive brain metastasis progressio

Author:Zhao, Hong; Dong, Wenjuan; Xu, Shan; Wang, Shiruo; Puri, Akshjot; Vasquez, Matthew; Gao, Dongbing; Yu, Xiaohui; Cui, Johnny; Lau, Johnson; Sampson, James; Sannes, Caitlin; Chang, Jenny; Wong, Stephen

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB256

3
Preclinical evaluation of a novel orally bioavailable MDM2 PROTAC, NW-8-461, in acute leukemia and myelofibrosi

Author:Zhang, Qinhong; Xu, Yajing; Wu, Qiong; Tu, Cecilia Z.; Wang, Shijia; Yin, Kai; Xu, Xuesong; Zhang, Zhang; Dai, Bing; Tan, Fenlai; Chen, Yi

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB038-LB038. DOI: 10.1158/1538-7445.AM2026-LB038

4
Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumor

Author:Zhang, Jinhui; Deng, Minjuan; Jiang, Bin; Li, Jie; Wang, Judy; Hamilton, Erika; Gao, Hua-Xin; Song, Xiaomin; Shen, Zhirong; Jin, Wei; Donate, Fernando

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-CT121

5
Towards a platform PBPK-QSP model for first-in-human dose selection of GenSci139, a potential best-in-class EGFR×HER2 bispecific ADC, in patients with cance

Author:Zhang, Fan; Xie, Yehua; Ma, Guangli; Liang, Xiao; Zhao, Xumin; Lin, Yihui; Ye, Xuan; Qi, Peng; Wang, Xiaozhen; Zhang, Haizhou; Zhang, Shu; Wang, Siqin; Jin, Lei

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB441

6
Whole body PBPK/PD modeling to support first-in-human dose selection for GenSci140, a potential best-in-class FRα biparatopic ADC, in patients with cance

Author:Zhang, Fan; Xie, Yehua; Ma, Guangli; Liang, Xiao; Zhao, Xumin; Lin, Yihui; Ye, Xuan; Qi, Peng; Wang, Xiaozhen; Zhang, Haizhou; Zhang, Shu; Wang, Siqin; Jin, Lei

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB442

7
AI guided engineering of pH responsive antibodies enables tumor selective targeting and improves the therapeutic inde

Author:Yu, Qilin; Chen, Mingchen; Lu, Ying; Wang, Yuxi

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB027-LB027. DOI: 10.1158/1538-7445.AM2026-LB027

8
TCE-A: An OR-gate CD19×CD20×CD3 trispecific T-cell engager for B-cell malignancies and autoimmune disease

Author:Ying, Hanxiao; Wu, Emily; Duan, Sizhu; Bai, Dongmei; Wang, Jing; Pu, Pu; Zhang, Limin; Wang, Chunyue; Hu, Min; He, Feng

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. -. DOI: 10.1158/1538-7445.AM2026-LB270

9
A phse 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cell death induce

Author:Yao, Herui; Li, Ning; Yu, Henry Ninghui; Massimini, Giorgio; Zhao, Jianli; Wang, Shuhang; Zhao, Yiming; Yu, Yue; Lai, Xiuping; Lv, Xiaozhi; Wang, Shaoshan; Guo, Xia; Huang, Jiancheng; Tan, Fei; Song, Erwei

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. CT074-CT074. DOI: 10.1158/1538-7445.AM2026-CT074

10
Orally bioavailable BCL6 degrader HSK47977 featuring a novel CRBN ligand demonstrates potent antitumor activity and synergy with BCL2 inhibition in NH

Author:Xu, Jun; Meng, Qingyuan; Liao, Yuting; Zhang, Chen; Wei, Jing; Tang, Ruofeng; Dou, Caixia; Yang, Jie; Tang, Pingming; Chen, Zhen; Lu, Yao; Wang, Ju; Yan, Pangke

Journal: CANCER RESEARCH. 2026; Vol. 86, Issue 8, pp. LB039-LB039. DOI: 10.1158/1538-7445.AM2026-LB039


在线咨询

Cancer Research

国际简称:CANCER RES参考译名:癌症研究

年发文量:291 CiteScore:17 是否预警:否 Gold OA文章占比:35.17% 研究类文章占比:93.47%

杂志社联系方式:AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404

Cancer Research